L1551NE - Discovery of a Binary Companion

L1551NE is a very young (class 0 or I) low-mass protostar located close to the well-studied L1551 IRS5. We present here evidence, from 1.3mm continuum interferometric observations at ~1'' resolution, for a binary companion to L1551NE. The companion, whose 1.3mm flux density is ~1/3 that of the primary component, is located 1.43'' (~230 A.U. at 160pc) to the southeast. The millimeterwave emission from the primary component may have been just barely resolved, with deconvolved size ~0.82"x0.70" (~131x112 A.U.). The companion emission was unresolved (<100 A.U.). The pair is embedded within a flattened circum-binary envelope of size ~5.4'' x 2.3'' (~860 x 370 A.U.). The masses of the three components (i.e. from the cicumstellar material of the primary star and its companion, and the envelope) are approximately 0.044, 0.014 and 0.023 Mo respectively.Comment: 8 pages, 1 figur

Focused laser Doppler velocimeter

A system for remotely measuring velocities present in discrete volumes of air is described. A CO2 laser beam is focused by a telescope at such a volume, a focal volume, and within the focusable range, near field, of the telescope. The back scatter, or reflected light, principally from the focal volume, passes back through the telescope and is frequency compared with the original frequency of the laser, and the difference frequency or frequencies represent particle velocities in that focal volume

Discovery of a 500 pc shell in the nucleus of Centaurus A

Spitzer Space Telescope mid-infrared images of the radio galaxy Centaurus A reveal a shell-like, bipolar, structure 500 pc to the north and south of the nucleus. This shell is seen in 5.8, 8.0 and 24 micron broad-band images. Such a remarkable shell has not been previously detected in a radio galaxy and is the first extragalactic nuclear shell detected at mid-infrared wavelengths. We estimate that the shell is a few million years old and has a mass of order million solar masses. A conservative estimate for the mechanical energy in the wind driven bubble is 10^53 erg. The shell could have created by a small few thousand solar mass nuclear burst of star formation. Alternatively, the bolometric luminosity of the active nucleus is sufficiently large that it could power the shell. Constraints on the shell's velocity are lacking. However, if the shell is moving at 1000 km/s then the required mechanical energy would be 100 times larger.Comment: submitted to ApJ Letter

Immunohistochemical localization of collagen types I and VI in human skin wounds

A total of 74 human skin wounds were investigated and collagen types I and VI were localized in the wound area by immunohistochemistry. Collagen type I appeared in the form of ramifying string-like structures after approximately 5–6 days, but positive reactions in the form of a spot-like staining around isolated fibroblasts also occurred in a skin wound aged 4 days. Collagen VI was detectable after a post-infliction interval of at least 3 days showing a strongly positive reacting network associated with fibroblasts in the wound area. Both collagens appeared almost constantly after a wound age of 6–7 clays and could also be found in wounds aged a few months. Therefore, although a positive reaction for collagen type I in the form of string-like and ramifying structures around wound fibroblasts indicates a wound age of at least 5–6 days, a spot-like positive staining for collagen type I cannot exclude a wound age of at least 4 days. A positive staining for collagen type VI represents a post-infliction time of 3 days or more. The almost constant appearance of these collagen types suggests that negative results in a sufficient number of specimens indicate a wound age of less than 6–7 days, but cannot completely exclude longer post-infliction intervals. Since collagen type I and VI are also found in the granulation/scar tissue of lesions with advanced wound age, the immunohistochemical analysis of these proteins provides no further information for an age determination of older skin wounds

The Spitzer Space Telescope Mission

The Spitzer Space Telescope, NASA's Great Observatory for infrared astronomy, was launched 2003 August 25 and is returning excellent scientific data from its Earth-trailing solar orbit. Spitzer combines the intrinsic sensitivity achievable with a cryogenic telescope in space with the great imaging and spectroscopic power of modern detector arrays to provide the user community with huge gains in capability for exploration of the cosmos in the infrared. The observatory systems are largely performing as expected and the projected cryogenic lifetime is in excess of 5 years. This paper summarizes the on-orbit scientific, technical and operational performance of Spitzer. Subsequent papers in this special issue describe the Spitzer instruments in detail and highlight many of the exciting scientific results obtained during the first six months of the Spitzer mission.Comment: Accepted for publication in the Astrophyscial Journal Supplement Spitzer Special Issue, 22 pages, 3 figures. Higher resolution versions of the figures are available at http://ssc.spitzer.caltech.edu/pubs/journal2004.htm

Chlorine inactivation of Escherichia coli O157:H7.

We analyzed isolates of Escherichia coli O157:H7 (which has recently caused waterborne outbreaks) and wild-type E. coli to determine their sensitivity to chlorination. Both pathogenic and nonpathogenic strains were significantly reduced within 1 minute of exposure to free chlorine. Results indicate that chlorine levels typically maintained in water systems are sufficient to inactivate these organisms

Longitudinal Cognitive Performance of Alzheimer\u27s Disease Neuropathological Subtypes

Introduction: Alzheimer\u27s disease (AD) neuropathological subtypes (limbic predominant [lpAD], hippocampal sparing [HpSpAD], and typical [tAD]), defined by relative neurofibrillary tangle (NFT) burden in limbic and cortical regions, have not been studied in prospectively characterized epidemiological cohorts with robust cognitive assessments. Methods: Two hundred ninety-two participants with neuropathologically confirmed AD from the Religious Orders Study and Memory and Aging Project were categorized by neuropathological subtype based on previously specified diagnostic criteria using quantitative regional NFT counts. Rates of cognitive decline were compared across subtypes using linear mixed-effects models that included subtype, time, and a subtype-time interaction as predictors and four cognitive domain factor scores (memory, executive function, language, visuospatial) and a global score as outcomes. To assess if memory was relatively preserved in HpSpAD, non-memory factor scores were included as covariates in the mixed-effects model with memory as the outcome. Results: There were 57 (20%) with lpAD, 22 (8%) with HpSpAD and 213 (73%) with tAD. LpAD died significantly later than the participants with tAD (2.4 years, P = .01) and with HpSpAD (3.8 years, P = .03). Compared to tAD, HpSpAD, but not lpAD, performed significantly worse in all cognitive domains at the time of initial impairment and declined significantly faster in memory, language, and globally. HpSpAD did not have relatively preserved memory performance at any time point. Conclusion: The relative frequencies of AD neuropathological subtypes in an epidemiological sample were consistent with a previous report in a convenience sample. People with HpSpAD decline rapidly, but may not have a memory-sparing clinical syndrome. Cohort-specific differences in regional tau burden and comorbid neuropathology may explain the lack of clinicopathological correlation

Spitzer observations of a 24 micron shadow: Bok Globule CB190

We present Spitzer observations of the dark globule CB190 (L771). We observe a roughly circular 24 micron shadow with a 70 arcsec radius. The extinction profile of this shadow matches the profile derived from 2MASS photometry at the outer edges of the globule and reaches a maximum of ~32 visual magnitudes at the center. The corresponding mass of CB190 is ~10 Msun. Our 12CO and 13CO J = 2-1 data over a 10 arcmin X 10 arcmin region centered on the shadow show a temperature ~10 K. The thermal continuum indicates a similar temperature for the dust. The molecular data also show evidence of freezeout onto dust grains. We estimate a distance to CB190 of 400 pc using the spectroscopic parallax of a star associated with the globule. Bonnor-Ebert fits to the density profile, in conjunction with this distance, yield xi_max = 7.2, indicating that CB190 may be unstable. The high temperature (56 K) of the best fit Bonnor-Ebert model is in contradiction with the CO and thermal continuum data, leading to the conclusion that the thermal pressure is not enough to prevent free-fall collapse. We also find that the turbulence in the cloud is inadequate to support it. However, the cloud may be supported by the magnetic field, if this field is at the average level for dark globules. Since the magnetic field will eventually leak out through ambipolar diffusion, it is likely that CB190 is collapsing or in a late pre-collapse stage.Comment: 16 pages, 13 figures, accepted for publication in Ap

On Orbit Performance of the MIPS Instrument

The Multiband Imaging Photometer for Spitzer (MIPS) provides long wavelength capability for the mission, in imaging bands at 24, 70, and 160 microns and measurements of spectral energy distributions between 52 and 100 microns at a spectral resolution of about 7%. By using true detector arrays in each band, it provides both critical sampling of the Spitzer point spread function and relatively large imaging fields of view, allowing for substantial advances in sensitivity, angular resolution, and efficiency of areal coverage compared with previous space far-infrared capabilities. The Si:As BIB 24 micron array has excellent photometric properties, and measurements with rms relative errors of 1% or better can be obtained. The two longer wavelength arrays use Ge:Ga detectors with poor photometric stability. However, the use of 1.) a scan mirror to modulate the signals rapidly on these arrays, 2.) a system of on-board stimulators used for a relative calibration approximately every two minutes, and 3.) specialized reduction software result in good photometry with these arrays also, with rms relative errors of less than 10%

Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study

Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described. Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF. Animals: Three hundred and fifty-four dogs with MMVD and cardiomegaly. Materials and Methods: Prospective, blinded study with dogs randomized (ratio 1:1) to pimobendan (0.4-0.6 mg/kg/d) or placebo. Clinical, laboratory, and heart-size variables in both groups were measured and compared at different time points (day 35 and onset of CHF) and over the study duration. Relationships between short-term changes in echocardiographic variables and time to CHF or CRD were explored. Results: At day 35, heart size had reduced in the pimobendan group:median change in (Delta) LVIDDN -0.06 (IQR:-0.15 to + 0.02), P < 0.0001, and LA:Ao -0.08 (IQR:-0.23 to + 0.03), P < 0.0001. Reduction in heart size was associated with increased time to CHF or CRD. Hazard ratio for a 0.1 increase in Delta LVIDDN was 1.26, P = 0.0003. Hazard ratio for a 0.1 increase in Delta LA:Ao was 1.14, P = 0.0002. At onset of CHF, groups were similar. Conclusions and Clinical Importance: Pimobendan treatment reduces heart size. Reduced heart size is associated with improved outcome. At the onset of CHF, dogs treated with pimobendan were indistinguishable from those receiving placebo